Priority Health to cover FoundationOne genomic profiles

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Priority Health announced it plans to cover the FoundationOne and FoundationOne Heme genomic profiles for patients with cancer developed by Foundation Medicine Inc.

FoundationOne interrogates the entire coding region in 315 genes and select introns in 28 genes commonly altered in solid tumors, according to Foundation Medicine. FoundationOne Heme analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies, sarcomas and select pediatric cancers.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login